DK0790255T3 - Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor - Google Patents

Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor

Info

Publication number
DK0790255T3
DK0790255T3 DK97104656T DK97104656T DK0790255T3 DK 0790255 T3 DK0790255 T3 DK 0790255T3 DK 97104656 T DK97104656 T DK 97104656T DK 97104656 T DK97104656 T DK 97104656T DK 0790255 T3 DK0790255 T3 DK 0790255T3
Authority
DK
Denmark
Prior art keywords
clmf
cells
proteins
relates
present
Prior art date
Application number
DK97104656T
Other languages
English (en)
Inventor
Richard Anthony Chizzonite
Maurice Kent Gately
Ulrich Andreas Gubler
Jeffrey David W Alton J Hulmes
Yu-Ching Eugene Pan
Frank John Podlanski
Alvin Seth Stern
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27412641&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0790255(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0790255T3 publication Critical patent/DK0790255T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
DK97104656T 1989-12-22 1990-12-09 Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor DK0790255T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45570889A 1989-12-22 1989-12-22
US52093590A 1990-05-09 1990-05-09
US57228490A 1990-08-27 1990-08-27

Publications (1)

Publication Number Publication Date
DK0790255T3 true DK0790255T3 (da) 2007-11-26

Family

ID=27412641

Family Applications (4)

Application Number Title Priority Date Filing Date
DK97104682T DK0790308T3 (da) 1989-12-22 1990-12-09 Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
DK97104656T DK0790255T3 (da) 1989-12-22 1990-12-09 Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
DK97104860T DK0790309T3 (da) 1989-12-22 1990-12-09 Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod
DK90123670T DK0433827T3 (da) 1989-12-22 1990-12-09 Cytotoksisk lumfocytmodningsfaktor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK97104682T DK0790308T3 (da) 1989-12-22 1990-12-09 Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK97104860T DK0790309T3 (da) 1989-12-22 1990-12-09 Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod
DK90123670T DK0433827T3 (da) 1989-12-22 1990-12-09 Cytotoksisk lumfocytmodningsfaktor

Country Status (11)

Country Link
EP (4) EP0433827B1 (da)
JP (2) JP3238418B2 (da)
AT (4) ATE366311T1 (da)
AU (2) AU6834990A (da)
BG (1) BG60933B2 (da)
CA (3) CA2572802A1 (da)
DE (4) DE69034244T2 (da)
DK (4) DK0790308T3 (da)
HU (1) HU211879A9 (da)
IE (1) IE904694A1 (da)
NZ (1) NZ236545A (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
EP0375045A1 (en) * 1988-12-22 1990-06-27 Duphar International Research B.V New annelated indole derivatives
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1997046583A1 (fr) 1996-06-04 1997-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Nouvelle proteine de cytokine feline
CA2268276A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Gene expression and delivery systems and uses
JP2001503257A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド Ｉｌ―１２遺伝子発現および送達系および使用
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
JP2002241398A (ja) * 1997-06-03 2002-08-28 Chemo Sero Therapeut Res Inst 新規なイヌサイトカインタンパク質
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ES2256027T3 (es) 1999-08-09 2006-07-16 Emd Lexigen Research Center Corp. Complejos de anticuerpos que contienen multiples citoquinas.
EP1905832A3 (en) * 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
KR100894359B1 (ko) * 1999-09-09 2009-04-22 쉐링 코포레이션 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
AU2005202420B2 (en) * 1999-09-09 2008-08-07 Merck Sharp & Dohme Corp. Mammalian cytokines; related reagents and methods
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
MXPA02007733A (es) 2000-02-11 2004-09-10 Merck Patent Gmbh Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
PL206701B1 (pl) 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
JP4309662B2 (ja) 2001-05-03 2009-08-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍特異的組換え抗体およびその使用
RU2312677C9 (ru) 2001-12-04 2008-03-27 Мерк Патент Гмбх Иммуноцитокины с модулированной селективностью
PL211180B1 (pl) 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
JP2008523842A (ja) 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
PT1966238E (pt) * 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US7891807B2 (en) * 2009-06-11 2011-02-22 Ana Nichole Mansuy Decorative eyeglass temples
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
US10189151B2 (en) 2016-11-14 2019-01-29 Snap-On Incorporated Compact head body hammer
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
KR20210064315A (ko) 2018-09-24 2021-06-02 얀센 바이오테크 인코포레이티드 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441636A1 (en) * 1988-11-10 1990-05-10 The Wistar Institute Of Anatomy And Biology Natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor

Also Published As

Publication number Publication date
EP0433827B1 (en) 1998-03-04
EP0790309A1 (en) 1997-08-20
EP0790255A3 (en) 2000-03-01
DE69034244T2 (de) 2008-04-03
ATE369383T1 (de) 2007-08-15
EP0790255A2 (en) 1997-08-20
EP0433827A2 (en) 1991-06-26
NZ236545A (en) 1993-04-28
EP0790309B1 (en) 2007-07-25
BG60933B2 (bg) 1996-06-28
DE69034247D1 (de) 2007-09-06
DK0790308T3 (da) 2007-10-08
AU6834990A (en) 1991-06-27
CA2572802A1 (en) 1991-06-23
IE990006A1 (en) 2000-11-01
JPH05294999A (ja) 1993-11-09
JP3375949B2 (ja) 2003-02-10
JP3238418B2 (ja) 2001-12-17
IE990005A1 (en) 2000-11-01
ATE163675T1 (de) 1998-03-15
EP0433827A3 (en) 1992-07-01
CA2346997C (en) 2007-02-20
DE69032086T2 (de) 1998-09-17
CA2032653C (en) 2002-05-28
IE990007A1 (en) 2000-11-01
JP2002167400A (ja) 2002-06-11
ATE368112T1 (de) 2007-08-15
DE69034249T2 (de) 2008-05-29
DE69034249D1 (de) 2007-09-20
CA2346997A1 (en) 1991-06-23
DE69034244D1 (de) 2007-08-16
AU5471294A (en) 1994-06-09
IE904694A1 (en) 1991-07-17
ATE366311T1 (de) 2007-07-15
DK0790309T3 (da) 2007-11-05
EP0790255B1 (en) 2007-08-08
DK0433827T3 (da) 1998-09-28
EP0790308A1 (en) 1997-08-20
CA2032653A1 (en) 1991-06-23
DE69032086D1 (de) 1998-04-09
AU674363B2 (en) 1996-12-19
DE69034247T2 (de) 2008-04-17
EP0790308B1 (en) 2007-07-04
HU211879A9 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
DK0790255T3 (da) Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
DE69332413D1 (de) Interleukin-2 analoge mit niedriger toxizität zur verwendung in der immuntherapie
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
FI864016A (fi) Med rekombinant-dna-teknik erhaollen kolonistimulerande faktor-1.
ATE167519T1 (de) T-zellen-wachstumsfaktor
ATE103494T1 (de) Verwendung von interleukin 2 zur behandlung von leukaemien.
IL102346A0 (en) Cysteine depleted il-6 muteins
Nishihara et al. Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide
IL82654A0 (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Ottmann et al. Proliferative effects of a recombinant human granulocyte colony-stimulating factor (rg-CSF) on highly enriched hematopoietic progenitor cells
BG60657B2 (en) Human recombinant interleukin-2 muteins
ES8703928A1 (es) Un metodo para preparar la proteina factor de estimulacion de colonias (csf-1)recombinante